Recombinant Human u-Plasminogen Activator/Urokinase, CF 1310-SE-010 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human u-Plasminogen Activator/Urokinase, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $454.00Supplier Page View Company Product Page
Catalog Number1310-SE-010
SpeciesHuman
FormatSupplied as a 0.2 µm filtered solution in HEPES, NaCl and CaCl2
Molecule Nameu-Plasminogen Activator (uPA)/Urokinase
Size10 ug
NCBI Full Gene Nameplasminogen activator, urokinase
NCBI Gene AliasesATF, BDPLT5, QPD, URK, u-PA, UPA
Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
Molecular WeightObserved: 18 kDa and 32 kDa, reducing conditions
Theoretical: 18 kDa (long A chain), 3 kDa (short A chain), 30 kDa (B chain)
ApplicationsEnzyme Activity
Conjugate/TagUnconjugated
Source/Expression SystemNS0-derived Recombinant Human u-Plasminogen Activator/Urokinase, CF
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 3 months, -20 to -70 °C under sterile conditions after opening

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Interactive Effects of IL-1β and TGF-β on Urokinase-Type Plasminogen Activator and α-Smooth Muscle Actin Expression by Corneal FibroblastsInvestigative ophthalmology & visual scienceJuly 1, 2025Sugioka K, Nishida T, Yunoki M, Mukai N, Murakami J, Kusaka S.

(2) Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47Molecular cancer therapeuticsApril 2, 2025Levengood MR, Carosino CM, Zhang X, Lucas S, Ortiz DJ, Westendorf L, Chin AP, Martin AD, Wong A, Hengel SM, et al.

(3) AND-gated protease-activated nanosensors for programmable detection of anti-tumour immunityNature nanotechnologyMarch 1, 2025Sivakumar A, Phuengkham H, Rajesh H, Mac QD, Rogers LC, Silva Trenkle AD, Bawage SS, Hincapie R, Li Z, Vainikos S, et al.

(4) Dysregulated fibrinolysis and plasmin activation promote the pathogenesis of osteoarthritisJCI insightMarch 19, 2024Wang Q, Shao G, Zhao X, Wong HH, Chin K, Zhao M, Bai A, Bloom MS, Love ZZ, Chu CR, et al.

(5) Intersection of Coagulation and Fibrinolysis by the Glycosylphosphatidylinositol (GPI)-Anchored Serine Protease TestisinInternational journal of molecular sciencesMay 26, 2023Buzza MS, Pawar NR, Strong AA, Antalis TM.

(6) Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable AntibodiesPharmaceuticsSeptember 2, 2021Howng B, Winter MB, LePage C, Popova I, Krimm M, Vasiljeva O.

(7) Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1Nature chemical biologyJuly 1, 2021Kryza T, Khan T, Lovell S, Harrington BS, Yin J, Porazinski S, Pajic M, Koistinen H, Rantala JK, Dreyer T, et al.

(8) p53 loss activates prometastatic secretory vesicle biogenesis in the GolgiScience advancesJune 1, 2021Tan X, Banerjee P, Shi L, Xiao GY, Rodriguez BL, Grzeskowiak CL, Liu X, Yu J, Gibbons DL, Russell WK, et al.ARF4 (11673-1-AP), MYH10 (19673-1-AP), ANXA2 (11256-1-AP) (ProteinTech); and recombinant PLAU protein (1310-SE-010) (R&D Systems). Vector construction The murine PAQR11, human PAQR11, human FAM3C, and human PLAU coding

(9) Plasminogen-Dependent Collagenolytic Properties of Staphylococcus aureus in Collagen Gel Cultures of Human Corneal FibroblastsInvestigative ophthalmology & visual scienceOctober 1, 2018Sugioka K, Kodama-Takahshi A, Sato T, Okada K, Murakami J, Park AM, Mishima H, Shimomura Y, Kusaka S, Nishida T.

(10) Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization PlatformJournal of medicinal chemistryMay 24, 2018Pant SM, Mukonoweshuro A, Desai B, Ramjee MK, Selway CN, Tarver GJ, Wright AG, Birchall K, Chapman TM, Tervonen TA, et al.

(11) Masked Chimeric Antigen Receptor for Tumor-Specific ActivationMolecular therapy : the journal of the American Society of Gene TherapyJanuary 4, 2017Han X, Bryson PD, Zhao Y, Cinay GE, Li S, Guo Y, Siriwon N, Wang P.

(12) Senescent peritoneal mesothelium creates a niche for ovarian cancer metastasesCell death & diseaseDecember 29, 2016Mikuła-Pietrasik J, Uruski P, Sosińska P, Maksin K, Piotrowska-Kempisty H, Kucińska M, Murias M, Szubert S, Woźniak A, Szpurek D, et al.

(13) An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair modeThe Journal of experimental medicineJune 1, 2015Doni A, Musso T, Morone D, Bastone A, Zambelli V, Sironi M, Castagnoli C, Cambieri I, Stravalaci M, Pasqualini F, et al.

(14) Imaging active urokinase plasminogen activator in prostate cancerCancer researchApril 1, 2015LeBeau AM, Sevillano N, Markham K, Winter MB, Murphy ST, Hostetter DR, West J, Lowman H, Craik CS, VanBrocklin HF.

(15) Gelsolin induces colorectal tumor cell invasion via modulation of the urokinase-type plasminogen activator cascadePloS oneJanuary 1, 2012Zhuo J, Tan EH, Yan B, Tochhawng L, Jayapal M, Koh S, Tay HK, Maciver SK, Hooi SC, Salto-Tellez M, et al.

(16) Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastasesCancer researchSeptember 15, 2010Endo-Munoz L, Cumming A, Rickwood D, Wilson D, Cueva C, Ng C, Strutton G, Cassady AI, Evdokiou A, Sommerville S, et al.

Be the First to Write a Review!

u-Plasminogen Activator (uPA)/Urokinase Protein

u-Plasminogen Activator (uPA)/Urokinase Protein

u-Plasminogen Activator (uPA)/Urokinase Protein

Recombinant Human u-Plasminogen Activator/Urokinase, CF from R&D Systems, a Bio-Techne Brand

R&D Systems, a Bio-Techne Brand

Citations (16)

Reviews

Recombinant Human u-Plasminogen Activator/Urokinase, CF from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map